Substance use disorders (SUDs) are extremely complex, with genetics influencing risk and treatment success. The National Institute of Drug Abuse Genetics Consortium (NIDA GRC) was founded in 1999 to coordinate efforts of investigators studying substance use disorders and addictive behaviors. Biological samples from this resource have been used to develop genomics-based data sets to understand abuse disorders and create genetic tools to predict disease and the efficacy of behavioral treatment. BioRealm has developed Smokescreen, a custom genome-wide platform to comprehensively understand and screen the genetics of SUDs. Since its launch, researchers have made use of the platform to screen over 50K participants. Concurrently, the platform has been used in conjunction with artificial intelligence (AI) to identify combinations of genotypes that can help predict opioid treatment success and assist smokers in quitting. This presentation will discuss both the NIDA genetics resource and the Smokescreen platform as it relates to NIDA’s mission.